PURPOSE: To evaluate the efficacy and safety of combination treatment with thalidomide and taxotere in patients with hormone-resistant prostate cancer.
MATERIALS AND METHODS: This clinical trial was performed on 16 patients with hormone-resistant prostate cancer.
RESULTS: Mean age of the participants was 72.7 ± 5.39 years (range, 65 to 85 years). In 94% of patients who received the drug combination, prostate-specific antigen level decreased more than 50%. The mean time to progression was 15 months and mean survival time was 23 months. This combination therapy had some adverse events.
CONCLUSION: Addition of anti-angiogenic agents, such as thalidomide, can improve therapeutic outcome in this group of patients.
Written by:
Rezvani H, Haghighi S, Ghadyani M, Attarian H. Are you the author?
Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Reference: Urol J. 2012 Fall;9(4):673-7.
PubMed Abstract
PMID: 23235972
